A carregar...
A Phase 1 Trial of Everolimus and Bevacizumab in Children with Recurrent Solid Tumors
BACKGROUND: Prognosis for children with recurrent solid tumors is generally poor. Targeting mammalian target of rapamycin (mTOR) and vascular endothelial growth factor A with everolimus and bevacizumab, respectively, synergistically improves progression-free survival and is well tolerated in adults...
Na minha lista:
| Publicado no: | Cancer |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7103504/ https://ncbi.nlm.nih.gov/pubmed/31967673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32722 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|